Prandial Metabolic Phenotyping in Sarcopenic Older Adults Comparing Plant Based and Whey Based Protein
Texas A&M University · NCT06628349
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 50–95 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 100
- US sites recruiting
- 1
- Study start
- February 1, 2024
- Record last updated
- November 25, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The researchers overall objective is to determine whether plant and animal protein based proteins affect the anabolic responses across aging populations differently due to specific changes in the essential amino acids (EAA) and non-essential amino acids (NEAA) kinetic responses. The researchers central hypothesis is that a high EAA to NEAA ratio in a protein meal is related to higher anabolic response to the meal. The researchers also hypothesize that the type of NEAA in a protein meal also affects the anabolic capacity of the meal. The researchers rationale is that finding the amino acid composition of a meal that will maximally induce protein anabolism will guide novel nutritional approaches to prevent and treat sarcopenia, thereby reducing both overall economic burden and improving individual patient outcomes.
Being studied: Whey Protein Isolate 90%; Soy Protein Isolate (90% Protein); Organic Pea Protein Isolate; Placebo (Water)
Conditions: Protein Metabolism
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Age 50-95 years old
- Diagnosis of Chronic Obstructive Pulmonary Disease (COPD); COPD group only
- Stable body-weight (±5%) for the past 3 months
- Ability to walk, sit down, and stand up (independently or with walking assistance device)
- Willingness to lay supine in bed for up to 6 hours
- Willingness and ability to comply with the protocol
Exclusion Criteria
- Established diagnosis and active treatment of chronic disease: Insulin dependent diabetes mellitus, active malignancy, heart disease, kidney disease, liver disease, HIV/AIDS, Asthma (moderate to severe), Hep (A,B, or C)
- History of untreated metabolic disease including hepatic or renal disorder
- Presence of acute illness or metabolically unstable chronic illness
- Hysterectomy
- Active dependence of alcohol or drugs
- Use of short course of oral corticosteroids within 4 weeks preceding study day
- Current use of long-term oral corticosteroids
- Use of protein or amino acids containing nutritional supplements within 5 days of the first study day
- Presence of fever within the last 3 days
- Planned elective surgery requiring 2 or more days of hospitalization during the entire study
- (Possible) pregnancy
- Failure to give informed consent or Investigator's uncertainty about the willingness or ability of the subject
- Already enrolled in another clinical trial
- Any condition according to the PI or nurse that was found during the screening visit, that would interfere with the study or safety of the patient
- Known allergy to any of the components of the feeding (soy, pea, or whey - dairy)
- Established daily diet of vegetarian / vegan composition
- \<23 MoCa score
Recruiting US locations
Texas A&M University - CTRAL
College Station, TX 77845
Site contact: Laura Ruebush · 979-218-5515 · le.ruebush@ctral.org
Study contacts (from the official record)
- Marielle Engelen, PhD · 979-220-2282 · mpkj.engelen@ctral.org
- Savanah Knezek, BS · 979-442-8468 · research@ctral.org
Similar studies in Texas
All healthy volunteers studies in Texas →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of LY4355756 in Healthy Participants
Eli Lilly and Company
- Location
- Dallas, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Phase I Study to Investigate the Pharmacokinetics and Safety of Capivasertib in Participants With Moderate Hepatic Impairment
AstraZeneca
- Location
- San Antonio, TX + 1 other US site
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight
Eli Lilly and Company
- Location
- San Antonio, TX
- Eligibility basics
- Ages 18–65
- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
Radiprodil in Participants With Hepatic Impairment
GRIN Therapeutics, Inc.
- Location
- DeSoto, TX + 1 other US site
- Eligibility basics
- Ages 18–75